Mitra, Shreya
Montgomery, Jeffrey E.
Kolar, Matthew J.
Li, Gang
Jeong, Kang J.
Peng, Bo
Verdine, Gregory L.
Mills, Gordon B.
Moellering, Raymond E.
Article History
Received: 30 June 2017
Accepted: 1 August 2017
First Online: 22 September 2017
Competing interests
: G.L.V. is a founder and shareholder at Aileron Therapeutics, which has been granted a license for commercial development of the stapled peptide technology used in this paper. The remaining authors declare no competing financial interests.